New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
10:55 EDTARWR, ISISArrowhead weakness related to Isis' competing HBV program, says Piper Jaffray
Arrowhead Research (ARWR) shares are lower after competitor ISIS Pharmaceuticals (ISIS) announced preclinical data on its antisense compound targeting hepatitis B virus. Piper anticipates Arrowhead will begin multi-dose ARC-520 Phase II studies in Q4 and reiterates its Overweight rating and $24 price target on Arrowhead.
News For ARWR;ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2014
07:50 EDTISISIsis Pharmaceuticals to host conference call
Management provides an update on the Phase 2 clinical studies of ISIS-SMN Rx results presented at the 19th International World Muscle Society Congress on a conference call to be held on October 10 at 11:30 am. Webcast Link
October 1, 2014
07:28 EDTISISLeerink to hold a roundtable
Subscribe for More Information
07:05 EDTISISIsis Pharmaceuticals earns $1.5M milestone payment from GSK
Subscribe for More Information
06:27 EDTARWRArrowhead management to meet with Jefferies
Subscribe for More Information
September 30, 2014
07:37 EDTISISIsis Pharmaceuticals management to meet with Deutsche Bank
Subscribe for More Information
September 29, 2014
08:25 EDTISISIsis Pharmaceuticals management to meet with Deutsche Bank
Meetings to be held in Baltimore/Philadelphia on September 29 hosted by Deutsche Bank.
September 26, 2014
10:01 EDTISISOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:20 EDTISISIsis Pharmaceuticals assumed with a Market Perform at Leerink
Subscribe for More Information
September 25, 2014
08:59 EDTISISSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
September 22, 2014
15:14 EDTISISIsis Pharmaceuticals management to meet with JPMorgan
Meeting to be held in Los Angeles on September 22 hosted by JPMorgan.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use